-
Something wrong with this record ?
Invasive measurement of hepatic venous pressure gradient before resection of hepatocellular carcinoma
P. Hříbek, J. Klasová, T. Tůma, J. Pudil, K. Menclová, T. Mačinga, E. Kubala, P. Urbánek
Status not-indexed Language English Country Poland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2015
Free Medical Journals
from 2015
PubMed Central
from 2015
Europe PubMed Central
from 2015
ROAD: Directory of Open Access Scholarly Resources
from 2015
- Publication type
- Journal Article MeSH
AIM OF THE STUDY: To evaluate the role of hepatic venous pressure gradient (HVPG) measurement in patients with resectable hepatocellular carcinoma (HCC) we describe our experience with the procedure as part of our hospital standard preoperative algorithm. We present our protocol for this situation, the HVPG measurement procedure, and the results of our cohort. MATERIAL AND METHODS: We performed a retrospective statistical analysis of all patients who underwent planned hepatic resection for HCC with HVPG measurement between 1/2016 and 1/2023. The cohort included 35 patients (30 males, mean age 69.5 years) who underwent HVPG measurement before liver resection for HCC. RESULTS: The success rate of measurement was 91.4%, with serious complications in 2.9% of cases. Due to the clinically significant portal hypertension (CSPH) 31.3% of patients were rejected for resection. Seventeen patients with excluded CSPH underwent resection with one case of a postoperative liver event, liver decompensation, representing 5.9% of them. One patient (5.9%) had a complicated postoperative course with fasciitis. None of the patients who underwent resection (88.2%) was readmitted to the hospital due to surgical complications or a liver event during 90 days of follow-up, and no death was reported. The median overall survival (OS) in the resected subgroup was 70 months (95% CI: 52-86), and in patients rejected for surgery (resection and transplantation) 35 months (95% CI: 13-48). CONCLUSIONS: HVPG measurement is the gold standard for the quantification of portal hypertension. Hepatic vein catheterization is invasive, but a safe procedure, with a clear impact on the management of resectable HCC.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23022861
- 003
- CZ-PrNML
- 005
- 20240529091920.0
- 007
- ta
- 008
- 240105s2023 pl f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5114/ceh.2023.130662 $2 doi
- 035 __
- $a (PubMed)37790686
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a pl
- 100 1_
- $a Hříbek, Petr $u Department of Medicine, 1 Faculty of Medicine, Charles University and Military University Hospital Prague, Praha, Czech Republic $u Department of Medicine, Faculty of Military Health Sciences, University of Defense, Hradec Králové, Czech Republic
- 245 10
- $a Invasive measurement of hepatic venous pressure gradient before resection of hepatocellular carcinoma / $c P. Hříbek, J. Klasová, T. Tůma, J. Pudil, K. Menclová, T. Mačinga, E. Kubala, P. Urbánek
- 520 9_
- $a AIM OF THE STUDY: To evaluate the role of hepatic venous pressure gradient (HVPG) measurement in patients with resectable hepatocellular carcinoma (HCC) we describe our experience with the procedure as part of our hospital standard preoperative algorithm. We present our protocol for this situation, the HVPG measurement procedure, and the results of our cohort. MATERIAL AND METHODS: We performed a retrospective statistical analysis of all patients who underwent planned hepatic resection for HCC with HVPG measurement between 1/2016 and 1/2023. The cohort included 35 patients (30 males, mean age 69.5 years) who underwent HVPG measurement before liver resection for HCC. RESULTS: The success rate of measurement was 91.4%, with serious complications in 2.9% of cases. Due to the clinically significant portal hypertension (CSPH) 31.3% of patients were rejected for resection. Seventeen patients with excluded CSPH underwent resection with one case of a postoperative liver event, liver decompensation, representing 5.9% of them. One patient (5.9%) had a complicated postoperative course with fasciitis. None of the patients who underwent resection (88.2%) was readmitted to the hospital due to surgical complications or a liver event during 90 days of follow-up, and no death was reported. The median overall survival (OS) in the resected subgroup was 70 months (95% CI: 52-86), and in patients rejected for surgery (resection and transplantation) 35 months (95% CI: 13-48). CONCLUSIONS: HVPG measurement is the gold standard for the quantification of portal hypertension. Hepatic vein catheterization is invasive, but a safe procedure, with a clear impact on the management of resectable HCC.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Klasová, Johana $u Department of Medicine, 1 Faculty of Medicine, Charles University and Military University Hospital Prague, Praha, Czech Republic
- 700 1_
- $a Tůma, Tomáš $u Department of Medicine, Faculty of Military Health Sciences, University of Defense, Hradec Králové, Czech Republic $u Department of Radiodiagnostic, Military University Hospital Prague, Praha, Czech Republic
- 700 1_
- $a Pudil, Jiří $u Department of Surgery, 2 Faculty of Medicine, Charles University and Military University Hospital Prague, Praha, Czech Republic
- 700 1_
- $a Menclová, Kateřina $u Department of Surgery, 2 Faculty of Medicine, Charles University and Military University Hospital Prague, Praha, Czech Republic
- 700 1_
- $a Mačinga, Tomáš $u Clinic of Oncology, 1 Faculty of Medicine, Charles University, Thomayer University Hospital Prague, Praha, Czech Republic $7 xx0317763
- 700 1_
- $a Kubala, Eugen $u Clinic of Oncology, 1 Faculty of Medicine, Charles University, Thomayer University Hospital Prague, Praha, Czech Republic
- 700 1_
- $a Urbánek, Petr $u Department of Medicine, 1 Faculty of Medicine, Charles University and Military University Hospital Prague, Praha, Czech Republic
- 773 0_
- $w MED00203266 $t Clinical and experimental hepatology $x 2392-1099 $g Roč. 9, č. 3 (2023), s. 236-242
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37790686 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240105 $b ABA008
- 991 __
- $a 20240529091916 $b ABA008
- 999 __
- $a ok $b bmc $g 2036426 $s 1209306
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 9 $c 3 $d 236-242 $e 20230823 $i 2392-1099 $m Clinical and experimental hepatology $n Clin Exp Hepatol $x MED00203266
- LZP __
- $a Pubmed-20240105